青少年Ad26.COV2.S的安全性和免疫性:第二阶段随机临床试验
Jelena Tica1, Veronica V Rezelj2, Benoit Baron3
1Scientific Affairs and Late Development, Janssen-Cilag GmbH, Neuss, Germany.
Human vaccines & immunotherapeutics
|January 27, 2025
概括
在12-17岁的青少年中,Ad26.COV2.S COVID-19疫苗的降低剂量是安全有效的. 疫苗引起了强大的抗体反应,与成人研究相美.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 免疫学 免疫学 免疫学
- 儿童传染病 儿童传染病
背景情况:
- Ad26.COV2.S COVID-19 疫苗已被批准用于成人使用.
- 青少年接种疫苗对于控制SARS-CoV-2传播至关重要.
研究的目的:
- 在12-17岁的健康青少年中评估Ad26.COV2.S减少剂量/剂量量的安全性和免疫性.
- 为了将免疫反应与成人疗效研究中观察到的免疫反应进行比较.
主要方法:
- 一个随机的第二阶段试验,涉及12-17岁的青少年.
- 用Ad26.COV2.S降低剂量 (0.625,1.25,或2.5 × 10^10病毒颗粒) 给药,分为1或2剂.
- 在接种疫苗后长达6个月的时间内评估安全性和幽默免疫性.
主要成果:
- 所有降低剂量方案都被很好地容忍,没有安全问题.
- 观察到强大的Spike结合抗体反应和病毒中和标位.
- 免疫反应至少持续了6个月,与成年人的免疫反应相当.
结论:
- 降低Ad26.COV2.S的剂量/剂量量显示了青少年可接受的安全性.
- 该疫苗在青少年中引起了强大而持久的幽默性免疫反应.
- 疫苗接种计划显示,与接受更高剂量的成年人抗体反应相似.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...


